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Abstract
Family studies suggest a genetic component to the etiology of chronic kidney disease (CKD) and end stage renal disease
(ESRD). Previously, we identified 16 loci for eGFR in genome-wide association studies, but the associations of these single
nucleotide polymorphisms (SNPs) for incident CKD or ESRD are unknown. We thus investigated the association of these loci
with incident CKD in 26,308 individuals of European ancestry free of CKD at baseline drawn from eight population-based
cohorts followed for a median of 7.2 years (including 2,122 incident CKD cases defined as eGFR ,60ml/min/1.73m2 at
follow-up) and with ESRD in four case-control studies in subjects of European ancestry (3,775 cases, 4,577 controls). SNPs at
11 of the 16 loci (UMOD, PRKAG2, ANXA9, DAB2, SHROOM3, DACH1, STC1, SLC34A1, ALMS1/NAT8, UBE2Q2, and GCKR) were
associated with incident CKD; p-values ranged from p=4.1e-9 in UMOD to p = 0.03 in GCKR. After adjusting for baseline
eGFR, six of these loci remained significantly associated with incident CKD (UMOD, PRKAG2, ANXA9, DAB2, DACH1, and STC1).
SNPs in UMOD (OR = 0.92, p = 0.04) and GCKR (OR = 0.93, p = 0.03) were nominally associated with ESRD. In summary, the
majority of eGFR-related loci are either associated or show a strong trend towards association with incident CKD, but have
modest associations with ESRD in individuals of European descent. Additional work is required to characterize the
association of genetic determinants of CKD and ESRD at different stages of disease progression.
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Introduction
Chronic kidney disease (CKD) and end stage renal disease
(ESRD) are associated with significant cardiovascular morbidity
and mortality, with substantial economic burden [1–4]. Diabetes
and hypertension are the primary risk factors for CKD and ESRD
[5–8] but do not fully account for CKD and ESRD risk [9–11].
Studies indicate familial aggregation of ESRD [12]. In African
Americans, high risk common variants in the MYH9/APOL1 locus
account for much of the excess genetic risk for non-diabetic ESRD
compared to their counterparts of European descent. In contrast,
comparable genetic risk loci of severe renal phenotypes have not
been identified in individuals of European ancestry [13–15].
Recently, 16 genetic risk loci associated with estimated glomerular
filtration rate (eGFR) and prevalent CKD were identified and
replicated by genome wide association studies (GWAS) in about
70,000 individuals of European ancestry in the CKDGen consor-
tium [16,17]. Two of these loci were also identified by an
independent consortium [18]. However, these studies focused on
eGFR and prevalent CKD (defined as eGFR,60 ml/min/1.73m2)
at one time point, which encompasses the entire spectrum of CKD,
and does not does not address the question of whether these genetic
factors are involved in the initiation of CKD or in the progression to
ESRD, the most advanced stage of CKD.We thus sought to analyze
the association of the previously identified 16 eGFR-associated loci
with the development of CKD and with ESRD in a total of over
34,000 individuals of European descent.
Results
Association of SNPs with Incident CKD
Overall, 26,308 individuals of European descent, from eight
population-based prospective studies, who were free of CKD at
baseline were included in the incident CKD analysis (Table 1). At
baseline, mean age ranged from 40.5 to 71.7 years. After a median
follow-up of 7.2 years, 2122 participants developed incident CKD.
Of the 16 SNPs analyzed, 11 were associated with incident
CKD (Table 2): SNPs in UMOD, PRKAG2, ANXA9, DAB2,
SHROOM3, DACH1, STC1, SLC34A1, ALMS1/NAT8, UBE2Q2
and GCKR showed p-values ranging from p=4.161029 in UMOD
to p = 0.03 in GCKR. The odds ratios (OR) for incident CKD of
the minor alleles at each of the 11 loci ranged from 0.76 per copy
of the T allele (allele frequency 18%) at the UMOD locus to 1.19
per copy of the A allele (allele frequency 22%) at PRKAG2. After
additional adjustment for baseline eGFR, 6 SNPs (at the UMOD,
PRKAG2, ANXA9, DAB2, DACH1 and STC1 loci) remained
significantly associated with incident CKD, with minimal
attenuation of effect size (Table 2).
At each of the significant loci, the direction and the magnitude
of the association was similar to those from the discovery analyses
Genetic Loci for Incident CKD and ESRD
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of eGFR and prevalent CKD [17]. For example, at the UMOD
locus, each copy of the minor T allele at rs12917707 was
associated with a 24% reduced risk for incident CKD, while in the
CKDGen consortium the same allele was associated with higher
eGFR [17]. Though the associations between incident CKD and
SNPs in SLC7A9, ATXN2, PIP5K1B and VEGFA were not
significant, the direction and magnitude of associations were
consistent with our previous findings for the phenotypes eGFR
and prevalent CKD [16,17]. TFDP2 was the only locus where we
did not observe association with incident CKD. Of the 16 SNPs
tested, 15 had the same direction of association with incident CKD
as their original associations with prevalent CKD. The probability
of observing this many SNPs with consistency in direction of
associations is 0.0002. We did not observe evidence for
heterogeneity between studies at any of the 16 loci (test for
heterogeneity p.0.05 for all SNPs).
Association of SNPs with ESRD
For the ESRD analysis, we included four case-control studies
with a total of 3775 ESRD patients and 4577 controls of European
descent without CKD (Table 3). Mean age ranged from 50.7 to 66.2
years in cases and from 47.7 to 62.1 years in controls. Although
the direction and magnitude of association for 8 SNPs (at the
UMOD, GCKR, PIP5K1B, PRKAG2, STC1, VEGFA, SHROOM3, and
ALMS1/NAT8 loci) were consistent with our previous findings
for eGFR and prevalent CKD [16,17], only two SNPs showed
nominally significant associations with ESRD (Table 2): rs1260326
in GCKR (OR= 0.93; p-value= 0.03) and rs12917707 in UMOD
(OR= 0.92; p-value= 0.04). The lack of association was not likely
due to heterogeneity of ESRD cases as only two SNPs showed
moderate heterogeneity in their associations with ESRD (Table 2):
rs4744712 at the PIP5K1B locus (p= 0.04 for heterogeneity) and
rs626277 at the DACH1 locus (p= 0.02 for heterogeneity).
Discussion
Among individuals of European Ancestry, most genetic loci
associated with the quantitative trait eGFR are also associated
with risk for initiation of CKD, with more than half of these
associations independent of eGFR at the baseline examination. In
contrast, only two SNPs were nominally associated with ESRD.
To date, the genetic loci showing significant and replicated
associations with ESRD are limited [13–15,19–26], and genetic
studies for incident CKD or for renal function decline in
established kidney disease are only recently emerging [27–29].
The loci we analyzed were identified in association with renal
function cross-sectionally and with prevalent CKD by GWAS in
the general population. Typical of many SNPs uncovered in
GWAS, the majority of these SNPs reside in intronic regions with
unknown functional consequences, although several are associated
with cis expression levels in liver tissue or leukocytes (Table S3)
[16,17]. These newly identified loci are non-overlapping with
those previously identified in individuals of European or Asian
descent with advanced diabetic nephropathy [19–26], or in
African Americans with non-diabetic ESRD [13–15].
For the ESRD analysis, we had adequate power to detect effects
that were similar to those for prevalent CKD in the discovery
GWAS, where odds ratios ranged from 0.8 to 1.19 [16,17]. In the
Table 1. Cohort characteristics of the incident CKD analysis (n = 26,308).
n
Incident CKD
cases, % (n)
Mean
Age
(yrs)
Women
(%)
DM
(%)
HTN
(%)
eGFR
(baseline)
eGFR
(follow-up)
Duration
between
baseline and
follow-up
(Years)
ARIC 8735 8.3 (728) 54.2 52.7 8.4 26.3 90.8 82.0 7.6
CHS 2389 12.3 (295) 71.7 60.8 11.4 33.2 86.2 83.9 5.9
CoLaus 1842 4.1 (75) 53.4 54.2 5.7 34.0 93.1 86.1 5.6
FHS incl original cohort 2313 10.5 (244) 57.6 54.0 7.9 27.9 92.0 81.2 10.9
KORA S3/F3 GWAS 1588 9.6 (153) 52.3 50.1 4.3 38.2 92.6 84.6 10.0
KORA S4/F4 GWAS 1737 5.3 (92) 53.4 51.2 3.4 33.4 90.8 86.1 7.1
KORA S3/F3 denovo 1235 3.3 (40) 40.5 51.7 1.6 22.7 99.4 94.2 9.7
KORA S4/F4 denovo 1149 4.1 (47) 41.1 52.6 1.7 20.7 98.9 93.9 7.2
Rotterdam Study 2236 12.6 (283) 66.6 58.6 7.9 49.5 79.5 74.5 6.4
SHIP 3084 5.3 (165) 49.2 51.8 11.2 53.1 92.4 90.6 5.3
doi:10.1371/journal.pgen.1002292.t001
Author Summary
Chronic kidney disease (CKD) affects about 6%–11% of the
general population, and progression to end stage renal
disease (ESRD) has a significant public health impact.
Family studies suggest that the risk for CKD and ESRD is
heritable. Unraveling the genetic underpinning of risk for
these diseases may lead to the identification of novel
mechanisms and thus diagnostic and therapeutic tools. We
have previously identified 16 genetic markers in associa-
tion with kidney function and prevalent CKD in general
population studies. However, little is known about the
relevance of these SNPs to the initial development of CKD
or to ESRD risk. Therefore, we have now analyzed the
association of these markers with the initiation of CKD in
more than 26,000 individuals from the general population
using serial estimations of kidney function, and with ESRD
in four case-control studies in subjects of European
ancestry (3,775 cases, 4,577 controls). We show that many
of the 16 markers are also associated or show a strong
trend towards association with initiation of CKD, while only
2 markers are nominally associated with ESRD. Further
work is required to characterize the association of genetic
determinants of different stages of CKD progression.
Genetic Loci for Incident CKD and ESRD
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present study, where associations were observed, the odds ratios
for ESRD tended to be smaller and ranged from 0.92 to 1.11.
There are several potential explanations for this effect dilution.
First, the mechanisms involved in the initiation of CKD, the
progression of CKD, and the incidence of ESRD may differ [30–
33]. Experimental animal data and gene expression profiling in
human kidney biopsies suggest differential biological pathways
contributing to kidney disease initiation and progression [34–36].
Second, the majority of patients with CKD die of cardiovascular
disease before developing ESRD [37–39]. Thus, the genetic
findings for kidney function in the general population may not
apply to the highly selected group of dialysis populations. Finally,
the process of progression from CKD to ESRD often involves
repeated insults including episodes of acute kidney injury by
diagnostic and operative procedures and therapies [40–43],
cardiac function deterioration [44], variation in access to adequate
health care [45,46] and other non-genetic factors [47]. Jointly,
these factors may further decrease the relative impact of the small
effects of SNPs derived from GWAS of eGFR in the general
population at the earliest stage of disease initiation.
The observed small effect sizes for ESRD in our study are in
contrast to the large effect sizes observed in relatively small cohorts
of individuals of African descent for variants in the MYH9/APOL1
locus, where odds ratios for ESRD ranged from 7.3 for the G1–G2
haplotype at the APOL1 locus to 2.38 for the E1 haplotype in the
MYH9 locus [13–15]. However, the strong effect at this locus is an
exceptional case and may be a consequence of a pronounced
positive selection against vulnerability for Trypanosoma brucei
rhodesiense infection at the price of a higher susceptibility for non-
diabetic ESRD in African Americans not observed in other
ethnicities. The establishment of large cohorts is thus needed for
performing GWAS of CKD initiation and progression as well as
ESRD to overcome the challenge of identifying novel loci
significantly associated with these phenotypes with small effect sizes.
The strength of our work lies in the large number of individuals
studied. Further, we exclusively analyzed candidate SNPs identified
by the unbiased method of GWAS [16,17]. However, some
limitations warrant mention. First, seven of the eight cohorts used
for the incident CKD analysis were also part of the CKDGen
discovery effort; thus the two samples are not entirely ‘‘independent’’.
However, the phenotype studied differs substantially: in Ko¨ttgen et al
[17], we used prevalent eGFR data including those with CKD, while
follow-up data in those without CKD at the baseline examination
was used for the present incident CKD analysis. In the present work,
we demonstrate robustness of our findings independent of baseline
GFR. Second, we relied on only two serum creatinine measurements
to define incident CKD, which may have introduced misclassifica-
tion and biased our findings towards the null. Third, we did not
account for pharmacological treatment with inhibitors of the renin-
angiotensin-aldosterone system. Since these drugs may affect kidney
function independently of kidney damage, their use may have diluted
observable genetic effects [48]. Fourth, our study was not designed to
detect fluctuations in eGFR. Furthermore, the etiology of ESRD in
the cases we examined may vary between studies, though we
observed a low degree of heterogeneity. Finally, our sample consisted
of individuals of European ancestry; findings may not be
generalizable to other ethnicities.
SNPs associated with eGFR in population-based studies are
associated with incident CKD, whereas modest associations were
observed with ESRD. Additional work is necessary to characterize
the genetic underpinnings across the full range of kidney disease
phenotypes, which could ultimately lead to novel diagnostic and
therapeutic strategies.
Materials and Methods
Ethics statement
In all studies, all participants gave informed consent. All studies
were approved by their appropriate Research Ethics Committees.
Study design and phenotype definition
In population based cohorts, serum creatinine measurements
were calibrated to the National Health and Nutrition Examination
Study (NHANES) standards in all studies to account for between-
laboratory variation across studies, as described previously
[10,16,17]. Using calibrated serum creatinine, we calculated the
estimated glomerular filtration rate (eGFR) with the 4-variable
MDRD equation [49].
For incident CKD, we analyzed studies of incident CKD in
eight population-based cohorts in the CKDGen consortium with
follow-up available: ARIC, CHS, CoLaus, FHS, KORA S3/F3,
KORA S4/F4, the Rotterdam Study and SHIP. Each study’s
design is shown in Text S1. Incident CKD cases were defined as
those free of CKD at baseline (defined as eGFR$60 ml/min/
1.73m2) but with a follow-up eGFR,60 ml/min/1.73m2. Con-
trols were those free of CKD at baseline and at follow-up.
Table 3. Characteristics of the ESRD case-control studies (n = 3,775 cases, n = 4,577 controls).1
n Mean Age (yrs) Women (%) DM (%) HTN (%)
ESRD cases GENDIAN 453 64.8 45.9 100.0 11.0
4D 1148 65.7 45.7 100.0 89.0
ArMORR 1244 66.2 47.8 23.6 39.9
CHOICE 518 59.0 42.5 45.8 13.3
FHKS 331 58.3 37.8 34.7 95.0
MMKD 81 50.7 37.0 0.0 96.3
Controls GENDIAN 326 62.1 43.3 100.0 32.2
KORA F3 denovo 1407 50.4 52.7 4.4 27.8
KORA F4 denovo 1130 47.7 52.3 3.2 12.2
SAPHIR 1714 51.3 36.6 3.3 56.0
1The four case-control studies comprised the following comparisons: GENDIAN cases versus GENDIAN controls, 4D versus KORA F3 denovo, ArMORR and CHOICE versus
KORA F4 denovo, FHKS and MMKD versus SAPHIR.
doi:10.1371/journal.pgen.1002292.t003
Genetic Loci for Incident CKD and ESRD
PLoS Genetics | www.plosgenetics.org 5 September 2011 | Volume 7 | Issue 9 | e1002292
For the ESRD analysis, we performed four case control studies
of ESRD. Cases were ESRD patients from six cohorts of ESRD
patients: CHOICE, ArMORR, GENDIAN, 4D, MMKD and
FHKS. Controls were those free of CKD (defined as
eGFR$60 ml/min/1.73m2) in three population-based cohorts
(KORA F3, KORA F4, SAPHIR) and one type 2 diabetes cohort
(GENDIAN). Each study’s design is shown in Text S1.
Statistical methods
In each study, we performed age- and sex adjusted logistic
regression of incident CKD, with and without additional adjusting
for baseline eGFR, or ESRD status with each SNP. In multicenter
studies further adjustment for study-center was performed to
account for possible differences between recruiting centers. For
family-based studies, we applied logistic regression via generalized
estimating equations (GEE) to account for the familial relatedness.
Study-specific results were then combined by meta-analysis using a
fixed effects model, using METAL (http://www.sph.umich.edu/
csg/abecasis/Metal/index.html) [50]. When significant heteroge-
neity between studies was observed (p for heterogeneity between
studies ,0.05) we used the random effects model [51]. Statistical
significance was defined as a one-sided p-value ,0.05 for each
SNP without adjustment for multiple testing since all SNPs
examined had strong prior probabilities of being associated with
the outcomes and the same alleles were hypothesized to be
associated with lower eGFR, incident CKD, and ESRD.
Power estimation
We used the QUANTO software for power estimation,
assuming an additive genetic model (http://hydra.usc.edu/GxE)
[52]. For the ESRD analysis and for SNPs with minor allele
frequency ranging from 0.2 to 0.4 we had 80–100% power to
detect an OR $ 1.10, whereas power was borderline for an OR of
1.05 to 1.09. For example, for the SNP rs12917707 at UMOD, we
had 100% power to detect an association with ESRD in the 3775
ESRD cases and 4577 controls assuming that the effect in ESRD
would be the same or larger than the effect observed for prevalent
CKD previously [16,17].
Genotyping methods and quality control
For the incident CKD analysis, we used the allele dosage
information of each of the 16 SNPs from each study’s genome
wide data set imputed to HAPMAP CEU samples described
previously [17,18]. Imputation provides a common SNP panel
across all studies to facilitate a meta-analysis across all contributing
SNPs. Information on each study’s genotyping and imputation
platform and quality control procedures are shown in Table S1.
Table S2 summarizes each SNPs imputation quality.
De novo genotyping of the 16 SNPs was performed in each of
the ESRD case-control studies as described previously [17].
Briefly, genotyping was performed either on a MassARRAY
system using Assay Design v.3.1.2 and the iPLEXTM chemistry
(Sequenom, San Diego, USA) at the Helmholtz Zentrum in
Munich, Germany (ArMORR, GENDIAN, 4D, MMKD, FHKS,
KORA S3/F3-subset without GWAS data, KORA S4/F4-subset
without GWAS data, SAPHIR); by using 59 nuclease allelic
discrimination assays on 7900HT Fast Real-Time Taqman PCR
genotyping systems (Applied Biosystems, Foster City, CA, USA) at
the Innsbruck Medical University (ArMORR, GENDIAN, 4D,
MMKD, FHKS, KORA F3-subset without GWAS data, KORA
F4-subset without GWAS data, SAPHIR); or as part of a larger
panel of 768 SNPs genotyped on the Illumina Bead Station
(CHOICE). The SNPs rs347685, rs11959928, rs4744712 and
rs12460876 were not available for de novo genotyping on the
Sequenom platform, thus the proxy SNPs rs6773343, rs11951093,
rs1556751 and rs8101881, with pairwise r2 of 1.0, 0.87, 0.87 and
1.0 respectively [53], were included in the MassARRAY multiplex
PCR.
For the obtained duplicate genotypes (9–22% of the subjects in
GENDIAN, 4D, MMKD, FHKS, KORA F3-subset without
GWAS data, KORA F4-subset without GWAS data, and
SAPHIR; no duplicate genotyping possible due to limited DNA-
availability in CHOICE and ArMORR) concordance was 96–
100% (median: 100%). SNPs with a per-study call rate ,90% or
with a per-study HWE p value ,0.0001 were excluded from
further analysis (rs6773343 and rs653178 in GENDIAN cases;
rs13538, rs267734, rs10109414, rs1394125 in ArMORR,
rs6773343, rs10109414, rs1556751, rs653178, rs8101881 in
CHOICE). In addition, individual samples with ,80% success-
fully genotyped SNPs were excluded from further analysis. After
these exclusions, call rates ranged from 91–100% (mean: 98%)
across all studies and all SNPs.
Supporting Information
Table S1 Genotyping and Imputation Platforms Used by
Studies in the incident CKD analysis.
(DOC)
Table S2 Imputation quality scores of SNPs across incident
CKD cohorts.
(DOC)
Table S3 Location and function of analyzed SNPs.
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Text S1 Study-specific details.
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